Tuesday, March 7, 2023

Rapport Therapeutics Gets $100M

San Diego- and Boston-based Rapport Therapeutics announced this morning that it has raised $100M in a Series A funding round, to go towards its precision medicines for neurological disorders. The funding was led by Third Rock Ventures, and also included ARCH Venture Partners and Johnson & Johnson Innovation. The company's lead compound focuses on treating seizure disorders. As part of the funding, the company named Abraham Ceesay as CEO.